"Designing Growth Strategies is in our DNA"

RNA interference (RNAi) Therapeutics Market Size, Share, and Industry Analysis, By Product (ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, LEQVIO, RIVFLOZA, and QFITLIA, and Others), By Molecule Type (siRNA, shRNA, miRNA-based Therapeutics, and Others), By Therapeutic Area (Cardiometabolic Diseases, Rare Genetic Diseases, Hepatic Diseases, Oncology, and Others), By Route of Administration (Subcutaneous, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail/Online Pharmacies, and Others), and Regional Forecast till 2034

Region : Global | Report ID: FBI119228 | Status : Ongoing

 

KEY MARKET INSIGHTS

The global RNA interference (RNAi) therapeutics market was valued at USD 5.50 billion in 2025. The market is projected to grow from USD 6.27 billion in 2026 to USD 18.00 billion by 2034, exhibiting a CAGR of 14.1% during the forecast period.

RNA interference (RNAi) therapeutics is emerging as an exponential growth area within precision medicine. RNAi therapies can silence disease-causing genes at the messenger RNA level. Unlike conventional drugs, these therapeutic solutions reduce the production of harmful proteins by targeting specific genetic messages. This makes them highly useful for diseases driven by clearly defined genetic or molecular targets. Furthermore, the market is gaining momentum as RNAi therapies move beyond rare diseases into larger treatment areas such as cardiometabolic diseases, hematology, and chronic liver-related disorders, creating wider opportunities for product development and commercialization.

  • For instance, in January 2026, Arrowhead Pharmaceuticals, Inc. announced that the Chinese National Medical Products Administration (NMPA) approved REDEMPLO (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).

Furthermore, new product launches, pipeline expansion, and partnerships by key operating companies strengthen their market position and support global market growth.

RNA interference (RNAi) Therapeutics Market Driver

Rising Adoption of Gene-Silencing Therapies to Treat Genetically Driven Diseases

The global market is growing as these gene-silencing therapies can directly target the genetic source of disease. Many rare and chronic diseases are caused by abnormal protein production, and RNAi therapies reduce this protein production by silencing specific messenger RNA. This targeted action improves treatment precision, supports better clinical outcomes, and encourages physicians, patients, and payers to adopt RNAi-based drugs where conventional therapies have limited disease-modifying impact. This has been observed as more approved RNAi products demonstrate clinical benefit across diseases. Pharmaceutical companies are increasing investment in RNAi platforms and expanding development into larger patient populations.

  • For instance, in June 2026, City Therapeutics, Inc., a biopharmaceutical company leading the RNA interference (RNAi)-based medicine, completed USD 99.5 million Series B financing. The investment aimed to accelerate the company’s RNAi engineering platform and pipeline, including ongoing Phase 1 clinical trial of CITY-FXI and two additional programs.

Download Free sample to learn more about this report.

According to Alnylam Pharmaceuticals, Inc., there are three types of PH: type 1 (PH1), type 2 (PH2), and type 3 (PH3). PH1 is the most common and the most severe form, accounting for 70% to 80% of all cases. PH1 affects approximately four individuals per million in the U.S. and Europe, with an estimated 1,300 to 2,100 diagnosed cases.  

RNA interference (RNAi) Therapeutics Market Restraint

High Treatment Cost and Specialty Access Requirements May Limit Wider Product Adoption

The global market faces a major restraint as most approved RNAi therapies are specialty medicines used for rare or complex diseases. These therapies require advanced discovery platforms, complex manufacturing, targeted delivery systems, and specialist-led patient management, which increases overall treatment cost. As a result, even when RNAi therapies show strong clinical value, their adoption can be slowed by reimbursement review, prior authorization, payer restrictions, and uneven access across countries. This creates a gap between clinical innovation and commercial uptake, especially in price-sensitive markets where healthcare systems may delay or restrict access to high-cost specialty drugs.

  • For instance, in 2026, Canada’s Drug Agency issued a draft reimbursement recommendation for AMVUTTRA (vutrisiran) in ATTR amyloidosis with cardiomyopathy, stating that the treatment should only be reimbursed under conditions, including specialist prescribing and cost conditions. The review also highlighted that, at the submitted price of USD 102,318.3 per pre-filled syringe, the annual treatment cost would be USD 409,273.2 per patient. The high therapy cost and reimbursement conditions slow wider adoption of RNAi therapeutics, despite strong clinical value.

RNA interference (RNAi) Therapeutics Market Opportunity

Growing Development of Extrahepatic RNAi Delivery Platforms to Open Doors to Untapped Treatment Areas

The global RNAi therapeutics market has a strong growth opportunity as companies develop delivery platforms that can move RNAi activity beyond the liver. At present, most approved RNAi products are liver-targeted as hepatocyte delivery is well established through GalNAc and lipid nanoparticle technologies. However, many high-value diseases affect tissues such as muscle, lung, heart, and the central nervous system, where commercial RNAi options are still limited. As extrahepatic delivery improves, companies can expand RNAi therapeutics into neuromuscular, pulmonary, cardiovascular, and other hard-to-treat diseases, which will increase the addressable patient population and create new revenue opportunities beyond the current rare liver-focused base.

  • For instance, in July 2025, Avidity Biosciences completed enrollment in the global Phase 3 HARBOR trial of delpacibart etedesiran, also known as del-desiran, for myotonic dystrophy type 1. The AOC platform demonstrated targeted delivery of RNA into muscle and that del-desiran was being evaluated in the first global Phase 3 trial in DM1. This highlights how extrahepatic RNA delivery can open new treatment areas for RNA-based therapeutics beyond liver-targeted diseases.

Segmentation

By Product

By Molecule Type

By Therapeutic Area

By Route of Administration

By Distribution Channel

By Region

·      ONPATTRO

·      AMVUTTRA

·      GIVLAARI

·      OXLUMO

·      LEQVIO

·      RIVFLOZA

·      QFITLIA

·      Others

·      siRNA

·      shRNA

·      miRNA-based Therapeutics

·      Others

·      Cardiometabolic Diseases

·      Rare Genetic Diseases

·      Hepatic Diseases

·      Oncology

·      Others

·      Subcutaneous

·      Intravenous

·      Others

·      Hospital Pharmacies

·      Specialty Pharmacies

·      Retail/Online Pharmacies

·      Others

·      North America (U.S. and Canada)

·      Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and the Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)

·      Latin America (Brazil, Mexico, and the Rest of Latin America)

·      Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)

Key Insights

The report covers the following key insights:

  • Overview of Technological Advancements in RNAi Delivery Platforms
  • Overview of Approved RNAi Therapeutics and Commercial Product Landscape
  • Pipeline Analysis, By Key Players
  • Regulatory Scenario, By Key Countries/Regions
  • Pricing, Reimbursement, and Market Access Scenario for Specialty RNAi Drugs
  • New Product Launches and Indication Expansions, By Key Players
  • Key Industry Developments (Mergers, Collaborations, and Acquisitions)

Analysis by Product

Based on product, the global RNA interference (RNAi) therapeutics market is segmented into ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, LEQVIO, RIVFLOZA, QFITLIA, and others.

The AMVUTTRA segment is likely to dominate the market. It has expanded from hereditary transthyretin-mediated amyloidosis with polyneuropathy into ATTR amyloidosis with cardiomyopathy, which has a larger diagnosed and treated patient base. This wider indication increases the number of eligible patients, while subcutaneous dosing improves convenience compared with older infusion-based RNAi treatment. As a result, AMVUTTRA has become the strongest revenue-generating RNAi product and is expected to hold the largest product-level share in the market.

  • For instance, in July 2025, Novartis AG received approval for a new indication from the U.S. FDA for Leqvio (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. The FDA proactively requested the label update based on the robust LDL-C-lowering data for PCSK9-targeting therapies.

Analysis by Molecule Type

Based on molecule type, the market is segmented into siRNA, shRNA, miRNA-based Therapeutics, and others.

The siRNA segment is likely to hold largest share in the market given that nearly all commercially approved RNAi therapeutics are siRNA-based products. Approved RNAi drugs use siRNA to degrade disease-related messenger RNA and reduce harmful protein production. In comparison, shRNA and miRNA-based therapeutics remain mainly in research or clinical-stage development and have limited commercial contribution. As a result, the market is currently shaped by siRNA products, while shRNA and miRNA-based therapeutics are expected to remain emerging categories until more approvals are achieved.

  • For instance, in December 2021, Novartis AG received approval from the U.S. FDA for LEQVIO (inclisiran), described as a small interfering RNA therapy for LDL-C reduction with two maintenance doses a year after initial dosing. This approval strengthened the commercial position of siRNA as the leading molecule type in RNAi therapeutics.

Analysis by Therapeutic Area

Based on therapeutic area, the market is segmented into cardiometabolic diseases, rare genetic diseases, hepatic diseases, oncology, and others.

The rare genetic diseases segment captured significant share in the RNA interference (RNAi) therapeutics market. The first approved RNAi therapies was developed for rare, genetically defined disorders where the disease-causing protein or pathway is well understood. These diseases often have high unmet need, limited treatment alternatives, and strong specialty-drug pricing. These factors allow RNAi therapies to generate considerable revenue even with smaller patient populations.

  • For instance, in November 2020, Alnylam Pharmaceuticals announced the U.S. FDA approval of OXLUMO (lumasiran) for primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Such developments are supporting the strong role of rare genetic diseases in the market.

Analysis by Route of Administration

Based on route of administration, the market is segmented into subcutaneous, intravenous, and others.

The subcutaneous administration segment dominated the market as most new RNAi therapeutics are designed for convenient injection instead of intravenous infusion. Subcutaneous dosing reduces treatment burden, supports outpatient administration, and improves patient convenience for chronic or long-term diseases. As companies continue to develop GalNAc-conjugated RNAi drugs, the market is shifting away from infusion-based products. This makes subcutaneous administration the strongest segment in the market.

  • For instance, in November 2019, Alnylam Pharmaceuticals announced the U.S. FDA approval of GIVLAARI (givosiran) injection for subcutaneous use for adults with acute hepatic porphyria. This supported the market shift toward injectable RNAi therapies that can be administered more conveniently than infusion-based products.

Analysis by Distribution Channel

Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, retail/online pharmacies, and others.

The specialty pharmacies segment is likely to dominate the market as RNAi therapeutics are high-value specialty medicines used for rare or complex diseases. These products often require benefits verification, prior authorization, cold-chain or specialty handling, patient onboarding, adherence support, and coordination with hospitals or specialist clinics. As a result, specialty pharmacies play a central role in ensuring access, reimbursement support, and continuity of therapy. Hospital pharmacies remain important for physician-administered or infusion-based treatment. Nevertheless, specialty pharmacies are expected to account for the largest share due to the growing use of subcutaneous RNAi products in outpatient specialty care.

  • For instance, in July 2025, Novartis AG received update from the U.S. FDA a label update for twice-yearly LEQVIO (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce LDL-C in adults with hypercholesterolemia.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, on the basis of region, is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 45.0% of the global RNA interference (RNAi) therapeutics market in 2025. The regional market is growing given that the region has a strong regulatory pathway for innovative therapies, a large specialty-drug ecosystem, and faster adoption of precision medicines for rare and chronic diseases. The U.S. has been an early approval market for several RNAi products, which gives companies confidence to launch therapies, expand indications, and invest in long-term clinical studies. In addition, the presence of leading RNAi companies, specialist treatment centers, and reimbursement support programs helps patients access high-value RNAi. Increasing research and development activities further support North America market growth.

  • For instance, in May 2026, Alnylam Pharmaceuticals announced new data analyses showing robust and consistent clinical benefit of vutrisiran across ATTR-CM patient populations, including patients with high disease burden. The company also highlighted a pooled analysis of more than 25,000 patient-years of experience with TTR-silencing RNAi therapies, supporting confidence in RNAi treatment adoption in North America.

The Europe market is expected to grow at a significant CAGR during the forecast period. The regulatory approvals are expanding RNAi use from rare disease treatment into broader cardiometabolic and amyloidosis-related indications leading to growth in the region. European healthcare systems are increasingly recognizing targeted gene-silencing therapies where long-term disease control and reduced treatment burden can improve patient outcomes. As more RNAi products receive European authorization, physicians gain more confidence in prescribing these therapies, while companies get stronger commercial visibility across major European markets.

  • For instance, in June 2025, Alnylam Pharmaceuticals announced that the European Commission approved AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy. The AMVUTTRA became the first RNAi therapeutic approved by the European Commission for wild-type or hereditary ATTR amyloidosis with cardiomyopathy, strengthening the commercial role of RNAi therapies in Europe.

The Asia Pacific market is expected to grow at a stable CAGR during the forecast period. The regional RNAi therapeutics market as countries such as Japan and China are gradually adding advanced RNAi products into their treatment landscape for rare diseases and cardiometabolic disorders. The region has a large patient pool for chronic diseases, growing specialist access, and increasing regulatory acceptance of innovative RNA-based therapies. As approved products expand in Japan and China, RNAi therapeutics are expected to move from limited rare-disease use toward broader adoption in cardiovascular and specialty-care settings.

  • For instance, in June 2025, Alnylam Japan announced that AMVUTTRA received an additional approval in Japan as a new treatment option for transthyretin amyloidosis with cardiomyopathy. This supports Asia Pacific market growth by expanding the use of RNAi therapy in Japan from polyneuropathy-focused ATTR treatment toward cardiomyopathy care.

Key Players Covered

The global RNA interference (RNAi) therapeutics market is moderately fragmented but increasingly consolidating.

The report includes the profiles of the following key players.

  • Alnylam Pharmaceuticals, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Sanofi (France)
  • Arrowhead Pharmaceuticals, Inc.(U.S.)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Amgen Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • Silence Therapeutics plc (U.K.)
  • Avidity Biosciences, Inc. (U.S.)

Key Industry Developments

  • December 2026: Sanofi received approval from the National Medical Products Administration (NMPA) in China for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura.
  • May 2025: Biogen Inc. collaborated with City Therapeutics, Inc leading the research and development of RNA interference (RNAi)-based medicine, to develop select novel RNAi therapies. Through the collaboration, the company leveraged its next-generation RNAi engineering technologies to develop an RNAi trigger molecule combined with proprietary drug delivery technology.
  • March 2025: Alnylam Pharmaceuticals, Inc. received approval from the U.S. FDA for Qfitlia (fitusiran), an RNAi therapeutic approved in the U.S., to lower antithrombin (AT).


  • Ongoing
  • 2025
  • 2021-2024
  • Special Price

    (Offer valid till 30th Nov 2026)

Download Free Sample

    man icon
    Mail icon
    Mail icon
Jump to Content

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Healthcare Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann